Supplemental Figure S1. (A) Patient plasma fulvestrant levels at day 28 and 84 as measured by LC/MS/MS; (B) Patient serum estradiol (E2) levels at baseline, day 28 and 84, measured by fluorescent-immuno-assay and corrected for fulvestrant cross-reactivity.
Supplemental Figure S2. Cross-reactivity between fulvestrant and estradiol (E2) fluorescent-immuno-assay.

$r^2 = 0.9978$